Skip to contentL
Lifecore Biomedical, Inc.
L
LFCRLifecore Biomedical, Inc. Q4 2023 · 10-K
Revenue$31.15M$31.15M+10.8% vs Q4 2022 Net Income-$38.90M-$38.90MderivedN/M vs Q4 2022 EPS Diluted-$1.32-$1.32N/M vs Q4 2022 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lifecore Biomedical, Inc. · CIK 1005286 · Engraved from SEC EDGAR
−25.4%
Operating Incomederived-$2,409,000N/M Operating Cash Flowderived-$2,262,000N/M Margins · derivedGross margin25.0%−12.1 pt vs Q4 2022
Operating margin-7.7%+3.3 pt vs Q4 2022
Net margin-124.9%+71.4 pt vs Q4 2022
ended May 28, 2023 · filed Mar 20, 2024 · 297 d after period end